Drug Trial Radar · NCT06948292
Role of QRX-3 in Chronic Kidney Disease Patients in Outpatients Clinics
Last checked: Nov 19, 2026Latest source record: Sep 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
127
Actual
Start
Mar 1, 2023
Primary completion
Aug 30, 2024
Study completion Oct 30, 2024
Sponsor
- Lead sponsor
- Ebima Clifford OkundayeIndustry
- Sponsor type
- Industry
- First posted
- Apr 29, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- Double (care provider, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
QRX-3, a new drug that stabilized the kidney renal tubular cell and increase the activity of NAD ( nicotinamide adenine dineuclotide )within the kidney cells; leading to decrease oxidative changes intracellularly, repair of renal tubular injury and restoration of optimized renal function above baseline , will be studied in patients with progressive chronic kidney disease over 12 months . The result of the change in renal function expressed as creatinine GFR (Glomerular filtration decline) over the treatment duration will be compared in the treatment group will be compared to control group without the medication during that same period .
Conditions
- Chronic Kidney Disease Stages 3-5
- Diabetic Kidney Disease
- Hypertensive Kidney Disease
Interventions
QRX-3Drug
phase 2B CKD study
Primary outcomes
What the sponsor says the trial is designed to measure.
- daily change in glomerular filtration rate by creatinine in mls/minTime frame: 12 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Neukidney Inc
Pasedena, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.